About RUBY-3
RUBY-3 is an ongoing, multiple-dose escalation, multi-cohort, open-label, Phase 12 basket study of povetacicept in autoimmune glomerulonephritis including IgA nephropathy, primary membranous nephropathy, lupus nephritis, and ANCA-associated vasculitis with glomerulonephritis, in which povetacicept will be administered subcutaneously for up to 104 weeks.
About Zai Lab
Zai Lab NASDAQ: ZLAB; HKEX: 9688 is an innovative, research-based, commercial-stage biopharmaceutical company headquartered in China and the United States. We are committed to addressing large unmet ivory coast telegram data medical needs in oncology, immunology, neuroscience and infectious diseases through the discovery, development and commercialization of innovative products. Our goal is to use our capabilities and resources to strive to promote the health and well-being of people in China and around the world. For more information about Zai Lab, please visit .zailaboratory or follow the company’s official WeChat account: Zai Lab.
This press release contains forward-looking statements concerning Zai Lab's future expectations, plans and prospects, including, but not limited to, statements regarding our prospects and plans for the development and commercialization of POWER in Greater China and Singapore, the potential benefits of POWER, and potential treatments for IgA nephropathy and other B-cell-mediated diseases. These forward-looking statements may contain words such as “aim,” “expect,” “believe,” “likely,” “estimate,” “anticipate,” “forecast,” “goal,” “intend,” “may,” “plan,” “likely,” “potential,” “will,” “would” and other similar expressions.